HC Wainwright Has Optimistic Outlook of AVXL Q1 Earnings

Anavex Life Sciences Corp. (NASDAQ:AVXL) – Equities researchers at HC Wainwright boosted their Q1 2025 earnings per share (EPS) estimates for Anavex Life Sciences in a research report issued to clients and investors on Thursday, December 26th. HC Wainwright analyst R. Selvaraju now forecasts that the biotechnology company will post earnings per share of ($0.17) for the quarter, up from their previous forecast of ($0.19). HC Wainwright currently has a “Buy” rating and a $42.00 target price on the stock. The consensus estimate for Anavex Life Sciences’ current full-year earnings is ($0.55) per share. HC Wainwright also issued estimates for Anavex Life Sciences’ Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at ($0.21) EPS and FY2025 earnings at ($0.73) EPS.

Separately, D. Boral Capital reissued a “buy” rating and issued a $46.00 target price on shares of Anavex Life Sciences in a research note on Monday, December 23rd.

Anavex Life Sciences Price Performance

AVXL opened at $12.11 on Monday. The company has a market capitalization of $1.03 billion, a price-to-earnings ratio of -24.22 and a beta of 0.73. The business’s 50-day moving average price is $8.29 and its two-hundred day moving average price is $6.44. Anavex Life Sciences has a 1 year low of $3.25 and a 1 year high of $14.44.

Anavex Life Sciences (NASDAQ:AVXL) last issued its quarterly earnings data on Monday, December 23rd. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.03.

Institutional Investors Weigh In On Anavex Life Sciences

A number of institutional investors have recently modified their holdings of the company. Geode Capital Management LLC grew its holdings in Anavex Life Sciences by 2.8% during the 3rd quarter. Geode Capital Management LLC now owns 1,883,199 shares of the biotechnology company’s stock valued at $10,699,000 after buying an additional 51,946 shares in the last quarter. Nwam LLC bought a new stake in shares of Anavex Life Sciences during the 3rd quarter valued at $5,172,000. Charles Schwab Investment Management Inc. increased its position in shares of Anavex Life Sciences by 2.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 665,976 shares of the biotechnology company’s stock valued at $3,783,000 after acquiring an additional 14,892 shares in the last quarter. Renaissance Technologies LLC increased its position in Anavex Life Sciences by 483.8% during the second quarter. Renaissance Technologies LLC now owns 466,437 shares of the biotechnology company’s stock valued at $1,968,000 after acquiring an additional 386,537 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its stake in shares of Anavex Life Sciences by 17.1% in the second quarter. Bank of New York Mellon Corp now owns 280,556 shares of the biotechnology company’s stock worth $1,184,000 after buying an additional 40,895 shares during the period. 31.55% of the stock is owned by institutional investors.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.